Clinical trial · Interventional
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
An Exploratory Study of 3-[18F]Fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in Patients With Neuroendocrine Tumors
NCT04510311CI-TRIAL-00113965completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [123I] metaiodobenzylguanidine | Drug | — | UNRESOLVED |
| 3-[18F]Fluoro-para-hydroxyphenethylguanidine | Drug | — | UNRESOLVED |
| Planar scintigraphy scan | Diagnostic Test | — | UNRESOLVED |
| Positron emission tomography/computed tomography scan | Diagnostic Test | — | UNRESOLVED |
| Single photon emission computed tomography/computed tomography scan | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PET/CT scan with radiotracer [18F]3F-PHPG
- description
- Novel radiotracer \[18F\]3F-PHPG prior to whole-body PET/CT scan.
- interventionNames
- Drug: 3-[18F]Fluoro-para-hydroxyphenethylguanidine
- Diagnostic Test: Positron emission tomography/computed tomography scan
- type
- ACTIVE_COMPARATOR
- label
- Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG
- description
- FDA approved radiotracer \[123I\]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures).
- interventionNames
- Drug: 3-[18F]Fluoro-para-hydroxyphenethylguanidine
- Drug: [123I] metaiodobenzylguanidine
- Diagnostic Test: Positron emission tomography/computed tomography scan
- Diagnostic Test: Planar scintigraphy scan
- Diagnostic Test: Single photon emission computed tomography/computed tomography scan
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Current neuroendocrine tumor diagnosis * Able to lie flat for 60 minutes * Provision of informed consent Exclusion Criteria: * Pregnancy or lactation * Claustrophobia * Inability to lie flat for 60 minutes * Currently taking medications that may alter PET scans of neuroendocrine tumors with these tracers, including any of the following: * Tricyclic antidepressants, which inhibit the norepinephrine transporter: desipramine, amitriptyline, imipramine * Cold medications containing the sympathomimetic amines: phenylephrine, phenylpropanolamine, pseudoephedrine * Nasal decongestants (some use phenylephrine as the active agent) * Cocaine (which inhibits the norepinephrine transporter) * Tetrabenazine (Xenazine), which inhibits the VMAT2 transporter * Monoamine oxidase inhibitors (MAOI) * Some antihypertensive drugs: reserpine, labetalol, α-methyldopa, clonidine
References
Publications (0)
Data not yet available
No reference posted for this study.